Cardiff Oncology’s Onvansertib: A Speculative Buy With Promising Data (NASDAQ:CRDF)
Today Headline,
Cardiff Oncology, Inc. (NASDAQ:CRDF) is a San Diego-based clinical-stage biotech focusing on developing innovative cancer…
Cardiff Oncology, Inc. (NASDAQ:CRDF) is a San Diego-based clinical-stage biotech focusing on developing innovative cancer…
Follow Summary Cardiff Oncology's Onvansertib is a first-in-class oral PLK1 inhibitor that targets difficult-to-treat cancers…
Follow Summary Cardiff Oncology is focused on developing a drug for colorectal cancer and pancreatic cancer, with promising…